The open-label safety study included patients from 3 Gocovri dyskinesia efficacy trials (N=223) and evaluated the long-term safety and tolerability of the treatment.
Mild traumatic brain injury is associated with increased risk of Parkinson disease among military veterans.
By 2 years, 30% of patients had increased their levodopa dose by ~300mg, indicating that treatment with Gocovri may allow for further levodopa optimization despite the occurrence of dyskinesia.
Adamas announced that Gocovri extended-release capsules are now available for the treatment of dyskinesia in Parkinson's patients.
The efficacy of focused ultrasound thalamotomy was evaluated for management of medically refractory, tremor-dominant Parkinson disease.
Neurology Advisor Articles
- US Opioid Overdose Deaths Reach Record Number
- Migraine Treatment in the ED: Overcoming Our Penchant for Opioids
- Erenumab as a Therapy for Hard to Treat Episodic Migraine
- Abnormalities in Genes Linked to IRSP in Alzheimer Disease
- Recommended Levels of Cardiovascular Risk Factors Associated With Cerebral Vessel Density, Flow
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Addressing Levodopa-Resistant Parkinson Disease
- High Daily Stress Linked to Migraine Prevalence in Women
- Researchers Identify Coffee Component That May Provide Neuroprotection
- Functional Imaging in Movement Disorders: Diagnostic Advantages
- Dextroamphetamine Plus Physical Therapy Nonsuperior to Placebo for Improving Post-Stroke Motor Recovery
- Nusinersen May Be Effective for Short-Term Motor Function Improvements in Spinal Muscular Atrophy